Retatrutide Research

How the Incretin Field Got Here

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Each generation addressed the previous one's constraint. Exenatide showed a protease-resistant GLP-1 agonist was possible. Liraglutide added albumin binding. Semaglutide extended it to weekly. Tirzepatide and retatrutide then added receptors rather than duration.

Key facts

Exenatide
Gila monster venom; natural DPP-4 resistance
Liraglutide
C16 palmitic; daily
Semaglutide
Aib8 + C18 diacid; weekly
Tirzepatide
Added GIP
Retatrutide
Added glucagon
Pattern
Duration first, then receptors

The first problem was survival

Native GLP-1 has a half-life of one to two minutes because DPP-4 removes its first two residues. Exenatide solved this by accident of biology: it is exendin-4 from Gila monster venom, carrying glycine where human GLP-1 has alanine, which DPP-4 cannot process. The first workable GLP-1 agonist was found rather than designed.

Then the problem was duration

Protease resistance does not prevent renal filtration. Liraglutide attached a C16 palmitic acid to bind albumin, reaching about 13 hours, enough for daily dosing. Semaglutide combined a stronger C18 diacid with an Aib substitution blocking DPP-4 directly, reaching roughly a week. Two generations of the same idea at increasing intensity.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Then the constraint changed

Once weekly dosing was achieved, extending duration further stopped being the bottleneck. Effect size became the limit, and the field turned from pharmacokinetics to pharmacology, adding receptors rather than adding hours. Tirzepatide added GIP; retatrutide added glucagon.

What retatrutide inherits

All of it. The albumin-binding lipid is liraglutide's idea at semaglutide's intensity. The protease-resistant design descends from exendin-4's accidental glycine. The GIP scaffold is tirzepatide's. Retatrutide is not a departure from the first-generation compounds so much as the accumulation of every solution they produced.

What stayed constant

Gastrointestinal adverse effects, at every generation and every receptor combination. They follow from GLP-1 receptor pharmacology itself (delayed gastric emptying and area postrema signalling) rather than from any design decision, which is why thirty years of engineering has not removed them.

And what changed direction

Orforglipron and aleniglipron abandon the peptide entirely, trading effect size for oral administration. That is the first real branch in the lineage rather than another step along it, and it is why 2026 looks like the year the field split rather than advanced.

Frequently asked questions

What was the first GLP-1 agonist?

Exenatide, a synthetic form of exendin-4 from Gila monster venom, which resists DPP-4 naturally because it carries glycine where human GLP-1 has alanine.

Why did the field stop extending half-life?

Once weekly dosing was achieved, duration stopped being the constraint. Effect size became the limit, so development turned to adding receptors.

Do the newer compounds have fewer side effects?

No. Gastrointestinal effects follow from GLP-1 receptor pharmacology itself and have persisted across every generation.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.